[go: up one dir, main page]

NO20073286L - Stabile krystallmodifikasjoner av DOTAP-klorid - Google Patents

Stabile krystallmodifikasjoner av DOTAP-klorid

Info

Publication number
NO20073286L
NO20073286L NO20073286A NO20073286A NO20073286L NO 20073286 L NO20073286 L NO 20073286L NO 20073286 A NO20073286 A NO 20073286A NO 20073286 A NO20073286 A NO 20073286A NO 20073286 L NO20073286 L NO 20073286L
Authority
NO
Norway
Prior art keywords
stable crystal
dotap chloride
crystal modifications
modifications
chloride
Prior art date
Application number
NO20073286A
Other languages
English (en)
Other versions
NO338885B1 (no
Inventor
Michael Platscher
Alfred Hedinger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20073286L publication Critical patent/NO20073286L/no
Publication of NO338885B1 publication Critical patent/NO338885B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/08—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører enantiomert rent DOTAP-klorid og stabile krystallmodifikasjoner av (2R,S)-, (2S)- og (2R)-DOTAP-klorid, en fremgangsmåte for fremstilling av disse modifikasjonene og anvendelsen derav som bestanddel for fremstillingen av medikamenter.
NO20073286A 2004-11-26 2007-06-25 Enantiomerisk rent (2R)-1,2-dioleoyloksy-3-trimetylammoniumpropanklorid ((2R) -DOTAP klorid), anvendelse derav som bestanddel ved fremstillingen av legemidler og farmasøytisk sammensetning derav. NO338885B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057303A DE102004057303A1 (de) 2004-11-26 2004-11-26 Stabile Kristallmodifikationen von DOTAP Chlorid
PCT/EP2005/011874 WO2006056312A1 (de) 2004-11-26 2005-11-07 Stabile kristallmodifikationen von dotap chlorid

Publications (2)

Publication Number Publication Date
NO20073286L true NO20073286L (no) 2007-06-25
NO338885B1 NO338885B1 (no) 2016-10-31

Family

ID=35789283

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073286A NO338885B1 (no) 2004-11-26 2007-06-25 Enantiomerisk rent (2R)-1,2-dioleoyloksy-3-trimetylammoniumpropanklorid ((2R) -DOTAP klorid), anvendelse derav som bestanddel ved fremstillingen av legemidler og farmasøytisk sammensetning derav.

Country Status (20)

Country Link
US (2) US8853283B2 (no)
EP (1) EP1814843B1 (no)
JP (1) JP4880612B2 (no)
KR (1) KR101249370B1 (no)
CN (2) CN101065350A (no)
AU (1) AU2005309107B2 (no)
BR (2) BRPI0518489B8 (no)
CA (1) CA2589218C (no)
DE (1) DE102004057303A1 (no)
ES (1) ES2545906T3 (no)
HU (1) HUE027554T2 (no)
IL (1) IL183324A (no)
MX (1) MX2007006128A (no)
NO (1) NO338885B1 (no)
NZ (2) NZ582382A (no)
PL (1) PL1814843T3 (no)
PT (1) PT1814843E (no)
RU (1) RU2463291C2 (no)
WO (1) WO2006056312A1 (no)
ZA (1) ZA200705169B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
SG194957A1 (en) * 2011-05-20 2013-12-30 Merck Patent Gmbh Stable crystal modifications of dotap chloride
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
CN104066444A (zh) * 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 癌ワクチンの組み合せ物
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CN110662532A (zh) * 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
EP0902682A2 (en) * 1996-05-08 1999-03-24 Nika Health Products Limited Cationic virosomes as transfer system for genetic material
ES2305157T3 (es) * 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
ES2183720B1 (es) * 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
ITMI20032185A1 (it) * 2003-11-12 2005-05-13 Chemi Spa Processo per la sintesi di lipidi cationici.

Also Published As

Publication number Publication date
CN101065350A (zh) 2007-10-31
AU2005309107B2 (en) 2011-07-21
CA2589218A1 (en) 2006-06-01
BRPI0518489B1 (pt) 2020-03-31
CN102796016B (zh) 2015-09-02
CA2589218C (en) 2013-12-17
BRPI0518489A2 (pt) 2008-11-25
BR122019018186B1 (pt) 2021-03-09
PT1814843E (pt) 2015-10-13
JP2008521757A (ja) 2008-06-26
RU2007123673A (ru) 2009-01-10
NZ556060A (en) 2010-03-26
BRPI0518489B8 (pt) 2021-05-25
US8853283B2 (en) 2014-10-07
JP4880612B2 (ja) 2012-02-22
EP1814843A1 (de) 2007-08-08
MX2007006128A (es) 2007-07-13
ES2545906T3 (es) 2015-09-16
US20080014254A1 (en) 2008-01-17
DE102004057303A1 (de) 2006-06-01
NZ582382A (en) 2010-08-27
AU2005309107A1 (en) 2006-06-01
EP1814843B1 (de) 2015-06-24
HK1178143A1 (zh) 2013-09-06
KR20070084501A (ko) 2007-08-24
US9457087B2 (en) 2016-10-04
KR101249370B1 (ko) 2013-04-01
IL183324A (en) 2013-10-31
IL183324A0 (en) 2007-09-20
CN102796016A (zh) 2012-11-28
PL1814843T3 (pl) 2015-11-30
NO338885B1 (no) 2016-10-31
RU2463291C2 (ru) 2012-10-10
WO2006056312A1 (de) 2006-06-01
US20140370081A1 (en) 2014-12-18
ZA200705169B (en) 2008-08-27
HUE027554T2 (en) 2016-10-28
BR122019018186B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
NO20073286L (no) Stabile krystallmodifikasjoner av DOTAP-klorid
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
DK1888541T3 (da) Benzo(d)isoxazol-3-yl-amin-forbindelser og anvendelse af disse som vanilloidreceptorligander
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
TW200716646A (en) (S)-N-methylnaltrexone
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20090175L (no) Stabile laquinimod sammensetninger
SG130189A1 (en) Substituted indole-o-glucosides
NO20090295L (no) Substituerte heteroarylderivater
DK1572707T3 (da) Hidtil ukendte aromatiske fluorglycosidderivater, lægemidler indeholdende disse forbindelser og anvendelse heraf
UA86042C2 (en) Substituted indazole-o-glucosides
DK1730131T3 (da) Glucopyranosyl-substituerede benzol-derivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
NO20084893L (no) Lyofiliserte terapeutiske peptistoffpreparater
NO20070046L (no) Nytt cykloheksanderivat, prodrug derav og salt derav, og terapeutisk middel inneholdende de samme for diabetes
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
PL1729746T3 (pl) Środki do przezskórnego podawania nikotyny
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TW200505875A (en) Novel compounds
TW200616995A (en) Novel compounds
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín